NG
NGQ1.F Medicure Inc
- Market cap
- EUR 28.8M
- P/E
- -
- P/B
- 3.37x
- ROE
- -31.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NGQ1.F undervalued?
Graham numberThe Graham number of Medicure Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medicure Inc fundamental analysis
No fundamental analysis for Medicure Inc yet.
Medicure Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-…
Full company profileMedicure Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medicure Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 37.8M | 27.1M | 29.1M | 20.2M | 11.6M | 21.7M | 23.1M | 21.7M | 21.9M | 28.9M | 30.7M |
| Gross Profit | 28.0M | 23.7M | 25.0M | 12.9M | 5.13M | 12.7M | 16.1M | 14.0M | 13.1M | 11.7M | 13.4M |
| Operating Income | 6.68M | 3.65M | -1.23M | -8.24M | -8.11M | -2.09M | 1.19M | -854K | -2.74M | -6.89M | -3.44M |
| EBITDA | - | 10.3M | 5.12M | -17.7M | -5.33M | 2.42M | 3.42M | 1.29M | 1.54M | -4.19M | -814K |
| Net Income | 27.7M | 43.4M | 3.93M | -19.8M | -6.85M | -727K | 1.37M | -922K | -1.04M | -7.10M | -3.67M |
| EPS | - | 2.75 | 0.25 | -1.83 | -0.67 | -0.07 | 0.13 | -0.09 | -0.10 | -0.68 | -0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 215M | 129M | 104M | 42.3M | 34.1M | 28.4M | 29.9M | 28.1M | 29.7M | 24.9M | 22.6M |
| Total Liabilities | 176M | 48.2M | 20.2M | 15.3M | 14.9M | 10.00M | 8.89M | 8.16M | 8.90M | 12.0M | 11.0M |
| Shareholders' Equity | 36.9M | 80.7M | 83.6M | 26.9M | 19.1M | 18.4M | 21.0M | 19.9M | 20.8M | 12.9M | 11.6M |
| Cash & Short-term Investments | 12.3M | 5.26M | 24.1M | 13.0M | 2.72M | 3.69M | 4.86M | 6.37M | 7.19M | 3.84M | 1.83M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.41M | 21.9M | 742K | -14.6M | -2.24M | 3.99M | 1.83M | 2.08M | 1.38M | -560K | -2.88M |
| Capital Expenditure | 464K | 1.20M | 197K | 186K | 2.00K | 377K | 310K | 270K | 739K | 0.00 | 0.00 |
| Free Cash Flow | - | 20.6M | -736K | -28.5M | -2.24M | 3.17M | 1.52M | 1.81M | 638K | -560K | -2.88M |
| Ratios | |||||||||||
| ROE | 75.0% | 53.8% | 4.7% | -73.4% | -35.8% | -3.9% | 6.5% | -4.6% | -5.0% | -55.0% | -31.7% |
| ROA | 12.9% | 33.7% | 3.8% | -46.8% | -20.1% | -2.6% | 4.6% | -3.3% | -3.5% | -28.4% | -16.2% |
| Net Profit Margin | 73.2% | 160.0% | 13.5% | -98.1% | -59.0% | -3.3% | 5.9% | -4.3% | -4.7% | -24.6% | -11.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Medicure Inc dividends
Medicure Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Nov 2, 2012.
Who owns Medicure Inc
- Insiders 27.13%
- Institutions 22.96%
- Public & others 49.92%
- Shares outstanding 10.4M
- Free float 5.22M
Medicure Inc company profile
- Company name
- Medicure Inc
- Ticker
- NGQ1.F
- ISIN
- CA58469E4085
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 2-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6
- Phone
- 204 487 7412
- Website
- medicure.com
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Medicure Inc management
3- Dr. Albert David Friesen Ph.D.Founder, CEO, President & Chairman of the Board · born 1947
- Mr. James F. Kinley C.A., CPAInterim CFO & Director · born 1978
- Dr. Reuben Saba Ph.D.Vice President of Scientific & Medical Affairs